Esophageal Cancer
Conditions
Keywords
Respiratory muscle strength, Diaphragmatic surface electromyography, Functional capacity
Brief summary
The purpose of this study is to investigate the effect of concurrent chemoradiation therapy on respiratory muscle performance, lung function and functional capacity in patients with local esophagus cancer.
Detailed description
This is a prospective observational study design. A total of 45 patients with newly diagnosed esophageal cancer will be recruited from the Mackay Memorial Hospital. All tests will be performed at baseline (prior to cancer treatment), weekly during treatment, prior to surgery, and one month after surgery. Tests will include demographic data collection, respiratory muscle performance (maximal inspiratory and expiratory pressure tests combined with diaphragmatic surface electromyography, and pulmonary functional test), dyspnea, and the functional exercise test (6-min walk test).Repeated measure ANOVA will be used for analyzing difference of parameters among various time points.
Interventions
None listed
Sponsors
Mackay Memorial Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* newly diagnosed primary esophageal cancer, aged more than 20 years, and communicate without difficulty
Exclusion criteria
* inability to perform inspiratory muscle training, the presence of unstable angina or myocardial infarction in recently one month, cannot cooperate with training protocols, and pregnancy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change of maximal inspiratory pressure (MIP) | Baseline, weekly during treatment, and 2 weeks after the completion of treatment | Change from baseline MIP at the end of each week's treatment, and 2 weeks after the completion of treatment |
| Change of diaphragmatic surface electromyography (EMGdi) | Baseline, weekly during treatment, and 2 weeks after the completion of treatment | Change from baseline EMGdi at the end of each week's treatment, and 2 weeks after the completion of treatment |
| Change of forced expiratory volume in one second (FEV1) | Baseline, weekly during treatment, and 2 weeks after the completion of treatment | Change from baseline FEV1 at the end of each week's treatment, and 2 weeks after the completion of treatment |
| Change of forced vital capacity (FVC) | Baseline, weekly during treatment, and 2 weeks after the completion of treatment | Change from baseline FVC at the end of each week's treatment, and 2 weeks after the completion of treatment |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change of functional exercise capacity | Baseline, weekly during treatment, and 2 weeks after the completion of treatment | Change from baseline 6-minute walking distance at the end of each week's treatment, and 2 weeks after the completion of treatment |
| Change of dyspnea | Baseline, weekly during treatment, and 2 weeks after the completion of treatment | Change from baseline Modified Borg Dyspnea score at the end of each week's treatment, and 2 weeks after the completion of treatment |
Countries
Taiwan
Outcome results
None listed